Found: 25
Select item for more details and to access through your institution.
A natural compound, methyl angolensate, induces mitochondrial pathway of apoptosis in Daudi cells.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 4, p. 583, doi. 10.1007/s10637-010-9393-7
- By:
- Publication type:
- Article
A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human [alpha] integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Anoikis induction and metastasis suppression by a new integrin [alpha]v[beta]3 inhibitor in human melanoma cell line m21.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Thioredxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrest.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 4, p. 627, doi. 10.1007/s10637-010-9401-y
- By:
- Publication type:
- Article
Factual understanding of randomized clinical trials: a multicenter case-control study in cancer patients.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 4, p. 700, doi. 10.1007/s10637-009-9315-8
- By:
- Publication type:
- Article
A novel structural derivative of natural alkaloid ellipticine, MDPSQ, induces necrosis in leukemic cells.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 4, p. 523, doi. 10.1007/s10637-009-9379-5
- By:
- Publication type:
- Article
Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 4, p. 688, doi. 10.1007/s10637-009-9382-x
- By:
- Publication type:
- Article
Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 4, p. 534, doi. 10.1007/s10637-009-9384-8
- By:
- Publication type:
- Article
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 4, p. 694, doi. 10.1007/s10637-010-9386-6
- By:
- Publication type:
- Article
Effects of the microtubule stabilizing agent peloruside A on the proteome of HL-60 cells.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 4, p. 544, doi. 10.1007/s10637-010-9387-5
- By:
- Publication type:
- Article
LYP, a novel bestatin derivative, inhibits cell growth and suppresses APN/CD13 activity in human ovarian carcinoma cells more potently than bestatin.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 4, p. 574, doi. 10.1007/s10637-010-9391-9
- By:
- Publication type:
- Article
Proposal for size justification of expanded cohort at phase-2-recommended dose.
- Published in:
- 2011
- By:
- Publication type:
- Report
AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 4, p. 554, doi. 10.1007/s10637-010-9389-3
- By:
- Publication type:
- Article
A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 4, p. 674, doi. 10.1007/s10637-010-9388-4
- By:
- Publication type:
- Article
Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 4, p. 680, doi. 10.1007/s10637-010-9396-4
- By:
- Publication type:
- Article
The anti-proliferative side effects of AEE788, a tyrosine kinase inhibitor blocking both EGF- and VEGF-receptor, are liver-size-dependent after partial hepatectomy in rats.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 4, p. 593, doi. 10.1007/s10637-010-9394-6
- By:
- Publication type:
- Article
Anticancer activity and mode of action of titanocene C.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 4, p. 607, doi. 10.1007/s10637-010-9395-5
- By:
- Publication type:
- Article
Cribrostatin 6 induces death in cancer cells through a reactive oxygen species (ROS)-mediated mechanism.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 4, p. 562, doi. 10.1007/s10637-010-9390-x
- By:
- Publication type:
- Article
Peloruside A inhibits microtubule dynamics in a breast cancer cell line MCF7.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 4, p. 615, doi. 10.1007/s10637-010-9398-2
- By:
- Publication type:
- Article
Avascular necrosis of the femoral head: a rare class-effect of anti-VEGF agents.
- Published in:
- 2011
- By:
- Publication type:
- Report
B1, a novel naphthalimide-based DNA intercalator, induces cell cycle arrest and apoptosis in HeLa cells via p53 activation.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 4, p. 646, doi. 10.1007/s10637-010-9403-9
- By:
- Publication type:
- Article
Baicalin induces human mucoepidermoid carcinoma Mc3 cells apoptosis in vitro and in vivo.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 4, p. 637, doi. 10.1007/s10637-010-9402-x
- By:
- Publication type:
- Article
Suppressive effects of liquid crystal compounds on the growth of the A549 human lung cancer cell line.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 4, p. 659, doi. 10.1007/s10637-010-9411-9
- By:
- Publication type:
- Article
Anoikis induction and metastasis suppression by a new integrin αvβ3 inhibitor in human melanoma cell line M21.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 4, p. 666, doi. 10.1007/s10637-010-9616-y
- By:
- Publication type:
- Article
The notorious 'drug lag' for oncology drugs in Japan.
- Published in:
- Investigational New Drugs, 2011, v. 29, n. 4, p. 706, doi. 10.1007/s10637-011-9638-0
- By:
- Publication type:
- Article